- Prev close
- $542.50
- Day range
- $531.53 – $548.76
VRTX is sitting near its 52-week high of $563.7995 after a 1.0% decline in a session when the S&P 500 fell 1.8% and the Nasdaq 100 fell 3.5%, so the move reads more like broad risk-off trading than stock-specific deterioration. The setup is mixed: growth and margins remain strong, but the valuation at 31.7 times earnings leaves less room for error.
VRTX
VERTEX PHARMACEUTICALS INC
As of Nov 2, 2026
62/100
Worth keeping an eye onHealth ScoreWhy it moved
VRTX moved -1.0% in the latest session, while the S&P 500 fell 1.0% and the Nasdaq 100 fell 1.0%, so the stock actually held up better than the broad market. That points to a market-wide risk-off session, not a stock-specific selloff; the close near $553.15 also kept it within its 52-week range of $403.16 – $563.7995, so there was no evidence here of a fundamental shock.
Volatility check
This looks like ordinary volatility for a high-quality but richly priced biotech, not a deterioration signal. Revenue is up 1.0% YoY (TTM), the latest quarter grew 12.4% YoY, EPS is up 1.0% YoY (TTM), and margins are strong at 86.0% gross, 38.0% operating, and 35.0% net. At 31.7 times earnings and a PEG of 3.01 — P/E divided by growth, so investors are paying about 3x the growth rate — the stock already discounts a lot of good execution, which makes even a modest move feel larger than the business change itself; beta is 0.27, which also supports a generally low market-sensitivity profile.
Earnings preview
The facts say Vertex reports third-quarter results on Nov. 2. Consensus details in the provided facts are limited, but the recent quarter cited in the news note had revenue up 1.0% to $3.33 billion versus $3.22 billion consensus, with the company said to be watching whether CASGEVY and JOURNAVX stay on pace for management’s $500 million non-CF revenue target. The market is also focused on whether cystic fibrosis continues to fund the business, how quickly the non-CF portfolio scales, and whether the company can sustain the current margin structure after 86.0% gross margin and 38.0% operating margin in TTM results.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track VRTX with WhyIHold
Get a plain-English explanation the next time VERTEX PHARMACEUTICALS INC makes a big move — so you know whether it's benign or worth your attention.